Abbott Laboratories
Abbott Laboratories ABT Peers
See (ABT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABT | $133.61 | +0.02% | 232.5B | 17.37 | $7.69 | +1.71% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $104.19 | -1.02% | 154.1B | 76.05 | $1.37 | N/A |
| SYK | $380.98 | -0.43% | 145.6B | 51.62 | $7.38 | +0.86% |
| MDT | $83.76 | +0.93% | 107.4B | 23.20 | $3.61 | +3.35% |
| EW | $78.11 | -0.15% | 45.8B | 32.27 | $2.42 | N/A |
| DXCM | $85.51 | -0.34% | 33.5B | 64.29 | $1.33 | N/A |
| STE | $242.02 | -1.30% | 23.8B | 39.35 | $6.15 | +0.92% |
| PODD | $325.00 | -0.01% | 22.9B | 58.45 | $5.56 | N/A |
| PHG | $22.82 | -0.95% | 21.1B | 78.69 | $0.29 | +3.89% |
Stock Comparison
ABT vs BSX-PA Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ABT is priced at $133.61, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ABT's ROE is +0.31%, compared to BSX-PA's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs BSX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BSX has a market cap of 154.1B. Regarding current trading prices, ABT is priced at $133.61, while BSX trades at $104.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BSX's P/E ratio is 76.05. In terms of profitability, ABT's ROE is +0.31%, compared to BSX's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs SYK Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SYK has a market cap of 145.6B. Regarding current trading prices, ABT is priced at $133.61, while SYK trades at $380.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SYK's P/E ratio is 51.62. In terms of profitability, ABT's ROE is +0.31%, compared to SYK's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs MDT Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, MDT has a market cap of 107.4B. Regarding current trading prices, ABT is priced at $133.61, while MDT trades at $83.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas MDT's P/E ratio is 23.20. In terms of profitability, ABT's ROE is +0.31%, compared to MDT's ROE of +0.09%. Regarding short-term risk, ABT is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs EW Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, EW has a market cap of 45.8B. Regarding current trading prices, ABT is priced at $133.61, while EW trades at $78.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas EW's P/E ratio is 32.27. In terms of profitability, ABT's ROE is +0.31%, compared to EW's ROE of +0.49%. Regarding short-term risk, ABT is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs DXCM Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, DXCM has a market cap of 33.5B. Regarding current trading prices, ABT is priced at $133.61, while DXCM trades at $85.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas DXCM's P/E ratio is 64.29. In terms of profitability, ABT's ROE is +0.31%, compared to DXCM's ROE of +0.24%. Regarding short-term risk, ABT is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs STE Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, STE has a market cap of 23.8B. Regarding current trading prices, ABT is priced at $133.61, while STE trades at $242.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas STE's P/E ratio is 39.35. In terms of profitability, ABT's ROE is +0.31%, compared to STE's ROE of +0.09%. Regarding short-term risk, ABT is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs PODD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, PODD has a market cap of 22.9B. Regarding current trading prices, ABT is priced at $133.61, while PODD trades at $325.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas PODD's P/E ratio is 58.45. In terms of profitability, ABT's ROE is +0.31%, compared to PODD's ROE of +0.35%. Regarding short-term risk, ABT is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs PHG Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, PHG has a market cap of 21.1B. Regarding current trading prices, ABT is priced at $133.61, while PHG trades at $22.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas PHG's P/E ratio is 78.69. In terms of profitability, ABT's ROE is +0.31%, compared to PHG's ROE of +0.03%. Regarding short-term risk, ABT is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ZBH Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ZBH has a market cap of 18B. Regarding current trading prices, ABT is priced at $133.61, while ZBH trades at $91.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ZBH's P/E ratio is 20.25. In terms of profitability, ABT's ROE is +0.31%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, ABT is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ABMD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ABT is priced at $133.61, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ABT's ROE is +0.31%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ABT is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs ALGN Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ALGN has a market cap of 12.9B. Regarding current trading prices, ABT is priced at $133.61, while ALGN trades at $178.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ALGN's P/E ratio is 32.46. In terms of profitability, ABT's ROE is +0.31%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, ABT is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs SNN Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SNN has a market cap of 12.8B. Regarding current trading prices, ABT is priced at $133.61, while SNN trades at $29.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SNN's P/E ratio is 31.01. In terms of profitability, ABT's ROE is +0.31%, compared to SNN's ROE of +0.08%. Regarding short-term risk, ABT is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs SWAV Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ABT is priced at $133.61, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ABT's ROE is +0.31%, compared to SWAV's ROE of +0.14%. Regarding short-term risk, ABT is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs PEN Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, PEN has a market cap of 9.9B. Regarding current trading prices, ABT is priced at $133.61, while PEN trades at $256.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas PEN's P/E ratio is 239.32. In terms of profitability, ABT's ROE is +0.31%, compared to PEN's ROE of +0.04%. Regarding short-term risk, ABT is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs GMED Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, GMED has a market cap of 8B. Regarding current trading prices, ABT is priced at $133.61, while GMED trades at $58.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas GMED's P/E ratio is 44.00. In terms of profitability, ABT's ROE is +0.31%, compared to GMED's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs BIO-B Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BIO-B has a market cap of 6.8B. Regarding current trading prices, ABT is priced at $133.61, while BIO-B trades at $250.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BIO-B's P/E ratio is -3.27. In terms of profitability, ABT's ROE is +0.31%, compared to BIO-B's ROE of -0.32%. Regarding short-term risk, ABT is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs BIO Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BIO has a market cap of 5.9B. Regarding current trading prices, ABT is priced at $133.61, while BIO trades at $216.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BIO's P/E ratio is -2.83. In terms of profitability, ABT's ROE is +0.31%, compared to BIO's ROE of -0.32%. Regarding short-term risk, ABT is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs BRKR Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BRKR has a market cap of 5.6B. Regarding current trading prices, ABT is priced at $133.61, while BRKR trades at $36.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BRKR's P/E ratio is 70.63. In terms of profitability, ABT's ROE is +0.31%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, ABT is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs GKOS Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, GKOS has a market cap of 5.4B. Regarding current trading prices, ABT is priced at $133.61, while GKOS trades at $94.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas GKOS's P/E ratio is -41.76. In terms of profitability, ABT's ROE is +0.31%, compared to GKOS's ROE of -0.17%. Regarding short-term risk, ABT is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs NARI Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ABT is priced at $133.61, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas NARI's P/E ratio is -59.24. In terms of profitability, ABT's ROE is +0.31%, compared to NARI's ROE of -0.18%. Regarding short-term risk, ABT is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs IRTC Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, IRTC has a market cap of 4.5B. Regarding current trading prices, ABT is priced at $133.61, while IRTC trades at $140.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas IRTC's P/E ratio is -44.94. In terms of profitability, ABT's ROE is +0.31%, compared to IRTC's ROE of -1.13%. Regarding short-term risk, ABT is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs TMDX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, TMDX has a market cap of 4.2B. Regarding current trading prices, ABT is priced at $133.61, while TMDX trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas TMDX's P/E ratio is 87.30. In terms of profitability, ABT's ROE is +0.31%, compared to TMDX's ROE of +0.22%. Regarding short-term risk, ABT is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ITGR Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ITGR has a market cap of 4.1B. Regarding current trading prices, ABT is priced at $133.61, while ITGR trades at $117.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ITGR's P/E ratio is 54.73. In terms of profitability, ABT's ROE is +0.31%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, ABT is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs INSP Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, INSP has a market cap of 3.9B. Regarding current trading prices, ABT is priced at $133.61, while INSP trades at $133.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas INSP's P/E ratio is 61.35. In terms of profitability, ABT's ROE is +0.31%, compared to INSP's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs AXNX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ABT is priced at $133.61, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ABT's ROE is +0.31%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ABT is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs PRCT Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, PRCT has a market cap of 3.2B. Regarding current trading prices, ABT is priced at $133.61, while PRCT trades at $57.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas PRCT's P/E ratio is -34.28. In terms of profitability, ABT's ROE is +0.31%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, ABT is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs LIVN Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, LIVN has a market cap of 2.4B. Regarding current trading prices, ABT is priced at $133.61, while LIVN trades at $43.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas LIVN's P/E ratio is -10.67. In terms of profitability, ABT's ROE is +0.31%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, ABT is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs NUVA Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ABT is priced at $133.61, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ABT's ROE is +0.31%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ABT is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ATEC Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ATEC has a market cap of 1.8B. Regarding current trading prices, ABT is priced at $133.61, while ATEC trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ATEC's P/E ratio is -10.79. In terms of profitability, ABT's ROE is +0.31%, compared to ATEC's ROE of -2.58%. Regarding short-term risk, ABT is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs UFPT Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, ABT is priced at $133.61, while UFPT trades at $232.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas UFPT's P/E ratio is 28.49. In terms of profitability, ABT's ROE is +0.31%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, ABT is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs CNMD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, ABT is priced at $133.61, while CNMD trades at $55.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas CNMD's P/E ratio is 14.54. In terms of profitability, ABT's ROE is +0.31%, compared to CNMD's ROE of +0.13%. Regarding short-term risk, ABT is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs TNDM Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $133.61, while TNDM trades at $20.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas TNDM's P/E ratio is -7.25. In terms of profitability, ABT's ROE is +0.31%, compared to TNDM's ROE of -0.83%. Regarding short-term risk, ABT is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs HSKA Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ABT is priced at $133.61, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ABT's ROE is +0.31%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ABT is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs AORT Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $133.61, while AORT trades at $28.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas AORT's P/E ratio is -56.29. In terms of profitability, ABT's ROE is +0.31%, compared to AORT's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs SSII Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SSII has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $133.61, while SSII trades at $6.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SSII's P/E ratio is -77.00. In terms of profitability, ABT's ROE is +0.31%, compared to SSII's ROE of -1.33%. Regarding short-term risk, ABT is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs AHCO Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, ABT is priced at $133.61, while AHCO trades at $8.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas AHCO's P/E ratio is 15.09. In terms of profitability, ABT's ROE is +0.31%, compared to AHCO's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs SILK Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $133.61, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SILK's P/E ratio is -18.96. In terms of profitability, ABT's ROE is +0.31%, compared to SILK's ROE of -0.29%. Regarding short-term risk, ABT is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs FNA Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ABT is priced at $133.61, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas FNA's P/E ratio is -19.83. In terms of profitability, ABT's ROE is +0.31%, compared to FNA's ROE of -0.36%. Regarding short-term risk, ABT is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs INMD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, INMD has a market cap of 998.2M. Regarding current trading prices, ABT is priced at $133.61, while INMD trades at $14.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas INMD's P/E ratio is 6.43. In terms of profitability, ABT's ROE is +0.31%, compared to INMD's ROE of +0.25%. Regarding short-term risk, ABT is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ESTA Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ESTA has a market cap of 982M. Regarding current trading prices, ABT is priced at $133.61, while ESTA trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ESTA's P/E ratio is -10.89. In terms of profitability, ABT's ROE is +0.31%, compared to ESTA's ROE of -2.10%. Regarding short-term risk, ABT is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs IART Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, IART has a market cap of 957.4M. Regarding current trading prices, ABT is priced at $133.61, while IART trades at $12.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas IART's P/E ratio is -32.42. In terms of profitability, ABT's ROE is +0.31%, compared to IART's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs CSII Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ABT is priced at $133.61, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas CSII's P/E ratio is -20.83. In terms of profitability, ABT's ROE is +0.31%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ABT is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs SIBN Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SIBN has a market cap of 803.7M. Regarding current trading prices, ABT is priced at $133.61, while SIBN trades at $18.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SIBN's P/E ratio is -29.94. In terms of profitability, ABT's ROE is +0.31%, compared to SIBN's ROE of -0.16%. Regarding short-term risk, ABT is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs IRMD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, IRMD has a market cap of 734.8M. Regarding current trading prices, ABT is priced at $133.61, while IRMD trades at $57.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas IRMD's P/E ratio is 37.28. In terms of profitability, ABT's ROE is +0.31%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ABT is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs CRY Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, ABT is priced at $133.61, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas CRY's P/E ratio is 425.71. In terms of profitability, ABT's ROE is +0.31%, compared to CRY's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs BFLY-WT Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BFLY-WT has a market cap of 654.7M. Regarding current trading prices, ABT is priced at $133.61, while BFLY-WT trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.31%, compared to BFLY-WT's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to BFLY-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs RXST Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, RXST has a market cap of 631.1M. Regarding current trading prices, ABT is priced at $133.61, while RXST trades at $15.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas RXST's P/E ratio is -23.53. In terms of profitability, ABT's ROE is +0.31%, compared to RXST's ROE of -0.10%. Regarding short-term risk, ABT is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs CBLL Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, CBLL has a market cap of 620.9M. Regarding current trading prices, ABT is priced at $133.61, while CBLL trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas CBLL's P/E ratio is -13.74. In terms of profitability, ABT's ROE is +0.31%, compared to CBLL's ROE of -1.64%. Regarding short-term risk, ABT is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs APEN Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ABT is priced at $133.61, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas APEN's P/E ratio is -9.43. In terms of profitability, ABT's ROE is +0.31%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ABT is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs BFLY Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BFLY has a market cap of 571.2M. Regarding current trading prices, ABT is priced at $133.61, while BFLY trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BFLY's P/E ratio is -7.70. In terms of profitability, ABT's ROE is +0.31%, compared to BFLY's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs AVNS Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, AVNS has a market cap of 558.6M. Regarding current trading prices, ABT is priced at $133.61, while AVNS trades at $12.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas AVNS's P/E ratio is -1.46. In terms of profitability, ABT's ROE is +0.31%, compared to AVNS's ROE of -0.37%. Regarding short-term risk, ABT is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs AXGN Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, AXGN has a market cap of 499.6M. Regarding current trading prices, ABT is priced at $133.61, while AXGN trades at $10.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas AXGN's P/E ratio is -68.56. In terms of profitability, ABT's ROE is +0.31%, compared to AXGN's ROE of -0.07%. Regarding short-term risk, ABT is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs KIDS Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, KIDS has a market cap of 494.9M. Regarding current trading prices, ABT is priced at $133.61, while KIDS trades at $19.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas KIDS's P/E ratio is -11.35. In terms of profitability, ABT's ROE is +0.31%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, ABT is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs NPCE Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, NPCE has a market cap of 427.7M. Regarding current trading prices, ABT is priced at $133.61, while NPCE trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas NPCE's P/E ratio is -15.90. In terms of profitability, ABT's ROE is +0.31%, compared to NPCE's ROE of -1.40%. Regarding short-term risk, ABT is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs BVS Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BVS has a market cap of 427.3M. Regarding current trading prices, ABT is priced at $133.61, while BVS trades at $6.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BVS's P/E ratio is -13.42. In terms of profitability, ABT's ROE is +0.31%, compared to BVS's ROE of -0.21%. Regarding short-term risk, ABT is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs OFIX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, OFIX has a market cap of 424.3M. Regarding current trading prices, ABT is priced at $133.61, while OFIX trades at $10.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas OFIX's P/E ratio is -2.93. In terms of profitability, ABT's ROE is +0.31%, compared to OFIX's ROE of -0.28%. Regarding short-term risk, ABT is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs SRDX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SRDX has a market cap of 421.4M. Regarding current trading prices, ABT is priced at $133.61, while SRDX trades at $29.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SRDX's P/E ratio is -21.05. In terms of profitability, ABT's ROE is +0.31%, compared to SRDX's ROE of -0.17%. Regarding short-term risk, ABT is less volatile compared to SRDX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs SENS Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SENS has a market cap of 397.7M. Regarding current trading prices, ABT is priced at $133.61, while SENS trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SENS's P/E ratio is -4.79. In terms of profitability, ABT's ROE is +0.31%, compared to SENS's ROE of -7.46%. Regarding short-term risk, ABT is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs SMLR Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SMLR has a market cap of 396.9M. Regarding current trading prices, ABT is priced at $133.61, while SMLR trades at $35.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SMLR's P/E ratio is -14.89. In terms of profitability, ABT's ROE is +0.31%, compared to SMLR's ROE of -0.21%. Regarding short-term risk, ABT is less volatile compared to SMLR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs TMCI Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, TMCI has a market cap of 361.1M. Regarding current trading prices, ABT is priced at $133.61, while TMCI trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas TMCI's P/E ratio is -6.75. In terms of profitability, ABT's ROE is +0.31%, compared to TMCI's ROE of -0.49%. Regarding short-term risk, ABT is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs CTKB Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, CTKB has a market cap of 358.4M. Regarding current trading prices, ABT is priced at $133.61, while CTKB trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas CTKB's P/E ratio is -31.44. In terms of profitability, ABT's ROE is +0.31%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, ABT is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs NNOX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, NNOX has a market cap of 333.5M. Regarding current trading prices, ABT is priced at $133.61, while NNOX trades at $5.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas NNOX's P/E ratio is -5.75. In terms of profitability, ABT's ROE is +0.31%, compared to NNOX's ROE of -0.30%. Regarding short-term risk, ABT is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs CLPT Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, CLPT has a market cap of 333.2M. Regarding current trading prices, ABT is priced at $133.61, while CLPT trades at $11.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas CLPT's P/E ratio is -15.51. In terms of profitability, ABT's ROE is +0.31%, compared to CLPT's ROE of -0.78%. Regarding short-term risk, ABT is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs VREX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, VREX has a market cap of 317.9M. Regarding current trading prices, ABT is priced at $133.61, while VREX trades at $7.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas VREX's P/E ratio is -7.44. In terms of profitability, ABT's ROE is +0.31%, compared to VREX's ROE of -0.08%. Regarding short-term risk, ABT is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs OM Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, OM has a market cap of 315.6M. Regarding current trading prices, ABT is priced at $133.61, while OM trades at $17.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas OM's P/E ratio is -0.62. In terms of profitability, ABT's ROE is +0.31%, compared to OM's ROE of -1.45%. Regarding short-term risk, ABT is less volatile compared to OM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs PACB Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, PACB has a market cap of 296.4M. Regarding current trading prices, ABT is priced at $133.61, while PACB trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas PACB's P/E ratio is -0.36. In terms of profitability, ABT's ROE is +0.31%, compared to PACB's ROE of -1.70%. Regarding short-term risk, ABT is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs VMD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, VMD has a market cap of 259.3M. Regarding current trading prices, ABT is priced at $133.61, while VMD trades at $6.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas VMD's P/E ratio is 21.87. In terms of profitability, ABT's ROE is +0.31%, compared to VMD's ROE of +0.10%. Regarding short-term risk, ABT is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs CERS Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, CERS has a market cap of 252.3M. Regarding current trading prices, ABT is priced at $133.61, while CERS trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas CERS's P/E ratio is -13.20. In terms of profitability, ABT's ROE is +0.31%, compared to CERS's ROE of -0.35%. Regarding short-term risk, ABT is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ZIMV Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ZIMV has a market cap of 251.6M. Regarding current trading prices, ABT is priced at $133.61, while ZIMV trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ZIMV's P/E ratio is -10.01. In terms of profitability, ABT's ROE is +0.31%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, ABT is less volatile compared to ZIMV. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs MXCT Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, MXCT has a market cap of 240.3M. Regarding current trading prices, ABT is priced at $133.61, while MXCT trades at $2.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas MXCT's P/E ratio is -5.65. In terms of profitability, ABT's ROE is +0.31%, compared to MXCT's ROE of -0.20%. Regarding short-term risk, ABT is less volatile compared to MXCT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs TCMD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, TCMD has a market cap of 229.9M. Regarding current trading prices, ABT is priced at $133.61, while TCMD trades at $9.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas TCMD's P/E ratio is 14.98. In terms of profitability, ABT's ROE is +0.31%, compared to TCMD's ROE of +0.08%. Regarding short-term risk, ABT is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs SNWV Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SNWV has a market cap of 224.5M. Regarding current trading prices, ABT is priced at $133.61, while SNWV trades at $26.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SNWV's P/E ratio is -4.21. In terms of profitability, ABT's ROE is +0.31%, compared to SNWV's ROE of +1.00%. Regarding short-term risk, ABT is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs NVRO Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ABT is priced at $133.61, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ABT's ROE is +0.31%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ABT is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs MASS Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, MASS has a market cap of 213.4M. Regarding current trading prices, ABT is priced at $133.61, while MASS trades at $5.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas MASS's P/E ratio is -2.68. In terms of profitability, ABT's ROE is +0.31%, compared to MASS's ROE of -0.13%. Regarding short-term risk, ABT is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs EYES Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, ABT is priced at $133.61, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas EYES's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.31%, compared to EYES's ROE of -0.26%. Regarding short-term risk, ABT is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs QTRX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, QTRX has a market cap of 203.9M. Regarding current trading prices, ABT is priced at $133.61, while QTRX trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas QTRX's P/E ratio is -4.23. In terms of profitability, ABT's ROE is +0.31%, compared to QTRX's ROE of -0.15%. Regarding short-term risk, ABT is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs SGHT Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, SGHT has a market cap of 201.1M. Regarding current trading prices, ABT is priced at $133.61, while SGHT trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas SGHT's P/E ratio is -3.97. In terms of profitability, ABT's ROE is +0.31%, compared to SGHT's ROE of -0.55%. Regarding short-term risk, ABT is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs TLSI Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, TLSI has a market cap of 200.5M. Regarding current trading prices, ABT is priced at $133.61, while TLSI trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas TLSI's P/E ratio is -4.82. In terms of profitability, ABT's ROE is +0.31%, compared to TLSI's ROE of +1.07%. Regarding short-term risk, ABT is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs BWAY Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BWAY has a market cap of 193.7M. Regarding current trading prices, ABT is priced at $133.61, while BWAY trades at $10.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BWAY's P/E ratio is 46.64. In terms of profitability, ABT's ROE is +0.31%, compared to BWAY's ROE of +0.06%. Regarding short-term risk, ABT is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs BSGM Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BSGM has a market cap of 189.8M. Regarding current trading prices, ABT is priced at $133.61, while BSGM trades at $6.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BSGM's P/E ratio is -13.12. In terms of profitability, ABT's ROE is +0.31%, compared to BSGM's ROE of +7.10%. Regarding short-term risk, ABT is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs CATX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, CATX has a market cap of 178.8M. Regarding current trading prices, ABT is priced at $133.61, while CATX trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas CATX's P/E ratio is -1.96. In terms of profitability, ABT's ROE is +0.31%, compared to CATX's ROE of -0.27%. Regarding short-term risk, ABT is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ELMD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ELMD has a market cap of 171.7M. Regarding current trading prices, ABT is priced at $133.61, while ELMD trades at $20.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ELMD's P/E ratio is 25.92. In terms of profitability, ABT's ROE is +0.31%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, ABT is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs INGN Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, INGN has a market cap of 171M. Regarding current trading prices, ABT is priced at $133.61, while INGN trades at $6.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas INGN's P/E ratio is -5.53. In terms of profitability, ABT's ROE is +0.31%, compared to INGN's ROE of -0.15%. Regarding short-term risk, ABT is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs CVRX Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, CVRX has a market cap of 169M. Regarding current trading prices, ABT is priced at $133.61, while CVRX trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas CVRX's P/E ratio is -3.03. In terms of profitability, ABT's ROE is +0.31%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, ABT is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs AVR Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, AVR has a market cap of 166.8M. Regarding current trading prices, ABT is priced at $133.61, while AVR trades at $4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas AVR's P/E ratio is -2.62. In terms of profitability, ABT's ROE is +0.31%, compared to AVR's ROE of -2.92%. Regarding short-term risk, ABT is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs PROF Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, PROF has a market cap of 165M. Regarding current trading prices, ABT is priced at $133.61, while PROF trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas PROF's P/E ratio is -4.54. In terms of profitability, ABT's ROE is +0.31%, compared to PROF's ROE of -0.70%. Regarding short-term risk, ABT is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ANIK Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ANIK has a market cap of 163.8M. Regarding current trading prices, ABT is priced at $133.61, while ANIK trades at $11.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ANIK's P/E ratio is -15.23. In terms of profitability, ABT's ROE is +0.31%, compared to ANIK's ROE of -0.33%. Regarding short-term risk, ABT is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs LNSR Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, LNSR has a market cap of 161M. Regarding current trading prices, ABT is priced at $133.61, while LNSR trades at $13.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas LNSR's P/E ratio is -2.78. In terms of profitability, ABT's ROE is +0.31%, compared to LNSR's ROE of -5.28%. Regarding short-term risk, ABT is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.
ABT vs RCEL Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, RCEL has a market cap of 159.7M. Regarding current trading prices, ABT is priced at $133.61, while RCEL trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas RCEL's P/E ratio is -2.76. In terms of profitability, ABT's ROE is +0.31%, compared to RCEL's ROE of -3.38%. Regarding short-term risk, ABT is less volatile compared to RCEL. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs BDMD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, BDMD has a market cap of 157.6M. Regarding current trading prices, ABT is priced at $133.61, while BDMD trades at $4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas BDMD's P/E ratio is 9.00. In terms of profitability, ABT's ROE is +0.31%, compared to BDMD's ROE of +0.12%. Regarding short-term risk, ABT is less volatile compared to BDMD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs RPID Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, RPID has a market cap of 151.2M. Regarding current trading prices, ABT is priced at $133.61, while RPID trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas RPID's P/E ratio is -3.35. In terms of profitability, ABT's ROE is +0.31%, compared to RPID's ROE of -0.56%. Regarding short-term risk, ABT is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs LUCD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, LUCD has a market cap of 126.5M. Regarding current trading prices, ABT is priced at $133.61, while LUCD trades at $1.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas LUCD's P/E ratio is -1.06. In terms of profitability, ABT's ROE is +0.31%, compared to LUCD's ROE of +26.96%. Regarding short-term risk, ABT is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs LUNG Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, LUNG has a market cap of 126M. Regarding current trading prices, ABT is priced at $133.61, while LUNG trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas LUNG's P/E ratio is -2.17. In terms of profitability, ABT's ROE is +0.31%, compared to LUNG's ROE of -0.64%. Regarding short-term risk, ABT is less volatile compared to LUNG. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ICAD Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ICAD has a market cap of 106.6M. Regarding current trading prices, ABT is priced at $133.61, while ICAD trades at $3.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ICAD's P/E ratio is -20.42. In terms of profitability, ABT's ROE is +0.31%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, ABT is less volatile compared to ICAD. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs MYO Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, MYO has a market cap of 104.5M. Regarding current trading prices, ABT is priced at $133.61, while MYO trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas MYO's P/E ratio is -20.75. In terms of profitability, ABT's ROE is +0.31%, compared to MYO's ROE of -0.36%. Regarding short-term risk, ABT is less volatile compared to MYO. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs OWLT Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, OWLT has a market cap of 100.8M. Regarding current trading prices, ABT is priced at $133.61, while OWLT trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas OWLT's P/E ratio is -3.79. In terms of profitability, ABT's ROE is +0.31%, compared to OWLT's ROE of +1.25%. Regarding short-term risk, ABT is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs HJLI Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ABT is priced at $133.61, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas HJLI's P/E ratio is N/A. In terms of profitability, ABT's ROE is +0.31%, compared to HJLI's ROE of -0.51%. Regarding short-term risk, ABT is less volatile compared to HJLI. This indicates potentially lower risk in terms of short-term price fluctuations for ABT.
ABT vs ASXC Comparison
ABT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABT stands at 232.5B. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, ABT is priced at $133.61, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABT currently has a P/E ratio of 17.37, whereas ASXC's P/E ratio is -1.12. In terms of profitability, ABT's ROE is +0.31%, compared to ASXC's ROE of -5.59%. Regarding short-term risk, ABT is more volatile compared to ASXC. This indicates potentially higher risk in terms of short-term price fluctuations for ABT.